Who are Placebo matching with Saxagliptin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): SGLT2 inhibitor and DPP-4 inhibitor, Sitagliptin phosphate/metformin hydrochloride FDC, CSII followed by Lina+MET, Pioglitazone + Alogliptin, Janumet, Lantus, Sitagliptin - DPP4i.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/placebo-matching-with-saxagliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Placebo matching with Saxagliptin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Placebo matching with Saxagliptin (Placebo matching with Saxagliptin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: DPP-4 inhibitor. Area: Diabetes.

phase 3 DPP-4 inhibitor DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo matching with Saxagliptin (Placebo matching with Saxagliptin) — AstraZeneca. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which increases the levels of incretin hormones, thereby enhancing glucose-dependent insulin secretion.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Placebo matching with Saxagliptin TARGET	Placebo matching with Saxagliptin	AstraZeneca	phase 3	DPP-4 inhibitor	DPP-4
SGLT2 inhibitor and DPP-4 inhibitor	SGLT2 inhibitor and DPP-4 inhibitor	LMC Diabetes & Endocrinology Ltd.	marketed	SGLT2 inhibitor and DPP-4 inhibitor combination	SGLT2 (sodium-glucose cotransporter 2) and DPP-4 (dipeptidyl peptidase-4)
Sitagliptin phosphate/metformin hydrochloride FDC	Sitagliptin phosphate/metformin hydrochloride FDC	Merck Sharp & Dohme LLC	marketed	DPP-4 inhibitor / biguanide combination	DPP-4 enzyme / metformin (AMPK pathway)
CSII followed by Lina+MET	CSII followed by Lina+MET	Sun Yat-sen University	marketed	Insulin therapy combined with DPP-4 inhibitor and biguanide	Insulin receptor (CSII); DPP-4 enzyme (linagliptin); mitochondrial glycerophosphate dehydrogenase (metformin)
Pioglitazone + Alogliptin	Pioglitazone + Alogliptin	Celltrion Pharm, Inc.	marketed	Thiazolidinedione + DPP-4 inhibitor combination	PPAR-γ and DPP-4
Janumet, Lantus	Janumet, Lantus	Chinese University of Hong Kong	marketed	DPP-4 inhibitor + biguanide (Janumet); long-acting basal insulin (Lantus)	DPP-4 enzyme, metformin (AMPK pathway), insulin receptor (Lantus)
Sitagliptin - DPP4i	Sitagliptin - DPP4i	Royal Devon and Exeter NHS Foundation Trust	marketed	DPP-4 inhibitor	DPP-4 (dipeptidyl peptidase-4)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (DPP-4 inhibitor class)

Merck Sharp & Dohme LLC · 5 drugs in this class
Daewoong Pharmaceutical Co. LTD. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
LG Life Sciences · 2 drugs in this class
Tanabe Pharma Corporation · 2 drugs in this class
Ain Shams University · 2 drugs in this class
Ono Pharmaceutical Co. Ltd · 2 drugs in this class
Cinnagen · 1 drug in this class
GRADE Study Group · 1 drug in this class
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo matching with Saxagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-matching-with-saxagliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab